4/A: EcoR1 Capital Amends SEC Filing to Correct Omitted Zymeworks Stock Transactions

EcoR1 Capital, a significant shareholder of Zymeworks Inc., filed an amended SEC Form 4 to include previously omitted stock purchases made in December 2024.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., filed an amended Form 4 with the SEC to correct an earlier filing.
• The amendment includes purchases of Zymeworks Inc. common stock that were inadvertently omitted from the original filing on December 23, 2024.
• The omitted transactions occurred on December 19, 2024, December 20, 2024, and December 23, 2024.
• On December 19, 2024, 298,818 shares were purchased at a weighted average price of $13.5289.
• On December 20, 2024, 704,488 shares were purchased at a weighted average price of $14.0776.
• On December 23, 2024, 251,502 shares were purchased at a weighted average price of $14.2508.
• The amended filing also removes a previously included transaction in pre-funded warrants from December 26, 2023, which was already reported in a prior filing.
• After these transactions, EcoR1 Capital and its related entities beneficially own 14,692,281 shares of Zymeworks Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly negative due to the initial reporting error, but the amendment corrects the issue. The increased shareholding is a positive sign, but the error tempers the overall sentiment.

Positives

• The amended filing provides a more accurate representation of EcoR1 Capital's recent transactions in Zymeworks stock.
• The increased shareholding demonstrates continued investment by EcoR1 Capital in Zymeworks.

Negatives

• The need for an amendment indicates an initial error in reporting, which could raise concerns about internal controls.
• The omission of transactions in the original filing could be seen as a lack of attention to detail.

Risks

• The need for an amended filing could lead to increased scrutiny from regulators.
• The market may react negatively to the initial reporting error, although the amendment should mitigate this.

Management Comments

• The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
• Scott Platshon, an employee of EcoR1, serves as a director of the Issuer and was nominated for the board by EcoR1 and the Funds.

Industry Context

This filing is a routine disclosure of stock transactions by a major shareholder, which is common in the biotech industry. It does not indicate any specific industry trend or competitive activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders in publicly traded companies.
• The level of detail provided in this filing is consistent with SEC requirements.
• The amendment highlights the importance of accurate and timely reporting of stock transactions.

Stakeholder Impact

• Shareholders will have a more accurate view of EcoR1 Capital's holdings in Zymeworks.
• The amendment may reassure investors that the reporting error has been corrected.

Key Dates

Keywords

EcoR1 Capital, Zymeworks Inc., SEC Form 4, stock purchase, beneficial ownership, amendment, Oleg Nodelman, shareholding